Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · IEX Real-Time Price · USD
1.51
-0.04 (-2.58%)
At close: Nov 28, 2023, 4:00 PM
1.48
-0.03 (-1.99%)
After-hours: Nov 28, 2023, 5:22 PM EST
Pyxis Oncology Stock Forecast
Stock Price Forecast
According to 3 stock analysts, the average 12-month stock price forecast for Pyxis Oncology stock is $12, which predicts an increase of 694.70%. The lowest target is $7.00 and the highest is $15. On average, analysts rate Pyxis Oncology stock as a strong buy.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 5, 2023.
Analyst Ratings
The average analyst rating for Pyxis Oncology stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '23 | Jul '23 | Aug '23 | Sep '23 | Oct '23 | Nov '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Initiates $7 | Buy | Initiates | $7 | +363.58% | Sep 5, 2023 |
| EF Hutton | EF Hutton | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +893.38% | Jul 31, 2023 |
| Credit Suisse | Credit Suisse | Buy Reiterates $14 | Buy | Reiterates | $14 | +827.15% | Mar 23, 2023 |
| B of A Securities | B of A Securities | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 2, 2021 |
| Jefferies | Jefferies | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Nov 2, 2021 |
Financial Forecast
Revenue This Year
170.00K
Revenue Next Year
680.00K
from 170.00K
Increased by 299.99%
EPS This Year
-2.00
from -3.65
EPS Next Year
-1.68
from -2.00
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | 525,000 | 2.1M | 2.1M | n/a | 12.8M |
| Avg | 170,003 | 680,003 | 680,003 | n/a | 6.2M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | - | 1,135.3% | 208.8% | - | - |
| Avg | - | 300.0% | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | -1.84 | -1.38 | -1.92 | -2.49 | -2.78 |
| Avg | -2.00 | -1.68 | -1.99 | -2.42 | -2.70 |
| Low | -2.24 | -1.91 | -1.98 | -2.32 | -2.60 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.